A potent and selective allosteric inhibitor of kidney-type glutaminase (GLS1), IC50 = 3.3 µM. Selective for GLS1 over GLS2, ɣ-glutamyl transpeptidase and glutamate dehydrogenase. Shuts down an alternative energy-generating glutaminolysis pathway in P493 cells under both glucose deprivation or hypoxia. Reduces the growth of P493 cell xenografts by 50% over a 10 day treatment. BPTES inhibition of glutamine utilization in cancer cells increases PD-L1 expression. Clears senescent cells and improves various age-related disorders in a geriatric mouse model.
Application Procedures
First dissolved in DMSO (10 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 2 months.
